Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fina Climent

Showing results (41-50 of 82) with videos related to

Pageof 9
Sort By:
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|November 23, 2019
Clinicopathologic features and prognostic significance of CD30 expression in <i>de novo</i> diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institutionMaría Queralt Salas, Fina Climent, Gustavo Tapia, et al.
Hematological Oncology|September 3, 2019
m7FLIPI and targeted sequencing in high-risk follicular lymphomaMarc Sorigue, Anna Oliveira, Santiago Mercadal, et al.
Histopathology|March 13, 2019
Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcomeLuis Veloza, Cristina Teixido, Natalia Castrejon, et al.
Breast Cancer Research and Treatment|July 10, 2012
Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practiceSonia Pernas, Miguel Gil-Gil, María Ochoa de Olza, et al.
Oncoimmunology|August 13, 2024
Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin LymphomaJosé L Solórzano, Victoria Menéndez, Edwin Parra, et al.
European Journal of Haematology|November 27, 2019
Long-term outcome comparing histological grades of follicular lymphoma patients treated with immunochemotherapy as first-line therapy: A retrospective analysis from two institutionsSantiago Mercadal, Juan-Manuel Sancho, Fina Climent, et al.
Disease Models & Mechanisms|May 14, 2021
Extramedullary multiple myeloma patient-derived orthotopic xenograft with a highly altered genome: combined molecular and therapeutic studiesLourdes Farre, Gabriela Sanz, Neus Ruiz-Xivillé, et al.
Histopathology|November 9, 2020
Cytokeratin expression in plasmablastic lymphoma - a possible diagnostic pitfall in the routine work-up of tumoursKatrin S Huettl, Annette M Staiger, Heike Horn, et al.
Haematologica|May 30, 2013
MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapyAlexandra Valera, Armando López-Guillermo, Teresa Cardesa-Salzmann, et al.
Stem Cell Reports|May 2, 2017
Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating PopulationJorge Gómez-Miragaya, Marta Palafox, Laia Paré, et al.
Pageof 9

Showing results (41-50 of 82) with videos related to

Sort By:
Pageof 9
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|November 23, 2019
Clinicopathologic features and prognostic significance of CD30 expression in <i>de novo</i> diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institutionMaría Queralt Salas, Fina Climent, Gustavo Tapia, et al.
Hematological Oncology|September 3, 2019
m7FLIPI and targeted sequencing in high-risk follicular lymphomaMarc Sorigue, Anna Oliveira, Santiago Mercadal, et al.
Histopathology|March 13, 2019
Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcomeLuis Veloza, Cristina Teixido, Natalia Castrejon, et al.
Breast Cancer Research and Treatment|July 10, 2012
Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practiceSonia Pernas, Miguel Gil-Gil, María Ochoa de Olza, et al.
Oncoimmunology|August 13, 2024
Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin LymphomaJosé L Solórzano, Victoria Menéndez, Edwin Parra, et al.
European Journal of Haematology|November 27, 2019
Long-term outcome comparing histological grades of follicular lymphoma patients treated with immunochemotherapy as first-line therapy: A retrospective analysis from two institutionsSantiago Mercadal, Juan-Manuel Sancho, Fina Climent, et al.
Disease Models & Mechanisms|May 14, 2021
Extramedullary multiple myeloma patient-derived orthotopic xenograft with a highly altered genome: combined molecular and therapeutic studiesLourdes Farre, Gabriela Sanz, Neus Ruiz-Xivillé, et al.
Histopathology|November 9, 2020
Cytokeratin expression in plasmablastic lymphoma - a possible diagnostic pitfall in the routine work-up of tumoursKatrin S Huettl, Annette M Staiger, Heike Horn, et al.
Haematologica|May 30, 2013
MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapyAlexandra Valera, Armando López-Guillermo, Teresa Cardesa-Salzmann, et al.
Stem Cell Reports|May 2, 2017
Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating PopulationJorge Gómez-Miragaya, Marta Palafox, Laia Paré, et al.
Pageof 9